B-MS' Hydroxyurea Effective In Sickle Cell

13 February 1995

Bristol-Myers Squibb's trial of Hydrea (hydroxyurea) in sickle cell anemia has been halted early by the National Heart, Lung and Blood Institute in the USA because the results are so compelling. The NHLBI has sent out a clinical alert to US physicians informing them of the results, which are believed to be the first evidence of an effective treatment for the disorder.

Hydroxyurea treatment halved the number of painful sickle cell episodes, the frequency of acute chest syndrome and the number of disease-associated blood transfusions. The trial included a total of 299 adult sickle cell sufferers, who had experienced at least three painful sickle episodes in the last 12 months. Each patient was started at a dose of 15mg/kg, which was increased in increments of 5mg/kg every 12 weeks until toxicity or the maximum allowable dose of 35mg/kg was reached.

Reversible bone marrow suppression was the only significant toxicity observed, although the clinical alert cautions that hydroxyurea may not be appropriate therapy for all patients, as it is a cytotoxic agent and could be dangerous, eg in women likely to become pregnant or in those unwilling or unable to follow direction regarding treatment. There have been some suggestions that protracted hydroxyurea may be associated with an increased risk of leukemia, so follow-up monitoring of the sickle cell patients is continuing.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight